Immunocore is a global commercial-stage biotechnology company,[1] based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

The core technology was spun out of Oxford University in 1999 by Bent Jakobsen into Avidex Ltd.[2] In July 2015, Immunocore announced the completion of an initial $320 million private financing round, Europe's largest ever financing round by a private life sciences company.

TCRs are often cited as aiding in recognising foreign antigens being presented by cells which have been infected by viruses or intracellular bacteria.

[11] In Jan 2022 the US FDA approved tebentafusp-tebn for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

[10] Immunocore's other pipeline programs include IMC-C103C, an ImmTAC candidate in Phase 1 partnered with Genentech for the treatment of solid tumors expressing MAGE-A4, and IMC-F106C, an ImmTAC candidate which is also in Phase 1 studies for solid tumors expressing PRAME.